The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?

Due to their durability, mechanical prostheses are frequently used for aortic valve replacement (AVR) in young adults. However, these valves are thrombogenic and require lifelong anticoagulation. Over the last few decades, efforts have been made towards the lowering of INR targets in an effort to re...

Full description

Saved in:
Bibliographic Details
Published in:Global Cardiology Science & Practice 2019-03, Vol.2019 (1), p.2-2
Main Authors: Bouhout, Ismail, El-Hamamsy, Ismail
Format: Article
Language:English
Subjects:
Lessons from the Trials
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 2
container_issue 1
container_start_page 2
container_title Global Cardiology Science & Practice
container_volume 2019
creator Bouhout, Ismail
El-Hamamsy, Ismail
description Due to their durability, mechanical prostheses are frequently used for aortic valve replacement (AVR) in young adults. However, these valves are thrombogenic and require lifelong anticoagulation. Over the last few decades, efforts have been made towards the lowering of INR targets in an effort to reduce bleeding events without influencing the thromboembolic risk. The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT) was designed to compare standard versus low anticoagulation targets in high-risk patients undergoing mechanical AVR with the ON-X prosthesis.
doi_str_mv 10.21542/gcsp.2019.2
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6472691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216291281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c218t-6e71d85dc944a2119c2a871c9105454282eb9d82a3b6c520688a4d8138d2d2883</originalsourceid><addsrcrecordid>eNpVkU1PGzEQhi3UqiDg1nPlI5XYsB7vh7eHVlFEC1KkIBQQN8trDxtXGzvY3lT013fDl6gPY4_96PXMvIR8ZvkEWFnAWafjZgI5ayawRw6A52VWC-Af3p33yXGMv_NxNTWvav6J7HOWQ9EUxQHZLldIr4KPG9TJbpFeK2f82v5FQxcuu6O3qh9vpy5Z7VU39CpZ7-ist85q1dNlsGM8ubpeTGfLr9_o3P_BQG2kLaaE4ZS2Q9qlNtHOe0PR-aFb_TgiH-9VH_H4ZT8kNz_Pl7OLbL74dTmbzjMNTKSswpoZURo91qqAsUaDEjXTDcvLYmxfALaNEaB4W-kS8koIVRjBuDBgQAh-SL4_626Gdo1Go0tB9XIT7FqFR-mVlf-_OLuSnd_KqqihatgocPIiEPzDgDHJtY0a-1459EOUAKyChoHYoafPqB7HGQPev33Dcvnklty5JXduSRjxL-9Le4NfveH_AJlgj9A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216291281</pqid></control><display><type>article</type><title>The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?</title><source>PubMed (Medline)</source><creator>Bouhout, Ismail ; El-Hamamsy, Ismail</creator><creatorcontrib>Bouhout, Ismail ; El-Hamamsy, Ismail</creatorcontrib><description>Due to their durability, mechanical prostheses are frequently used for aortic valve replacement (AVR) in young adults. However, these valves are thrombogenic and require lifelong anticoagulation. Over the last few decades, efforts have been made towards the lowering of INR targets in an effort to reduce bleeding events without influencing the thromboembolic risk. The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT) was designed to compare standard versus low anticoagulation targets in high-risk patients undergoing mechanical AVR with the ON-X prosthesis.</description><identifier>ISSN: 2305-7823</identifier><identifier>EISSN: 2305-7823</identifier><identifier>DOI: 10.21542/gcsp.2019.2</identifier><identifier>PMID: 31024944</identifier><language>eng</language><publisher>Qatar: Magdi Yacoub Heart Foundation</publisher><subject>Lessons from the Trials</subject><ispartof>Global Cardiology Science &amp; Practice, 2019-03, Vol.2019 (1), p.2-2</ispartof><rights>Copyright ©2019 The Author(s) 2019 The Author(s), licensee Magdi Yacoub Institute.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472691/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472691/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31024944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bouhout, Ismail</creatorcontrib><creatorcontrib>El-Hamamsy, Ismail</creatorcontrib><title>The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?</title><title>Global Cardiology Science &amp; Practice</title><addtitle>Glob Cardiol Sci Pract</addtitle><description>Due to their durability, mechanical prostheses are frequently used for aortic valve replacement (AVR) in young adults. However, these valves are thrombogenic and require lifelong anticoagulation. Over the last few decades, efforts have been made towards the lowering of INR targets in an effort to reduce bleeding events without influencing the thromboembolic risk. The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT) was designed to compare standard versus low anticoagulation targets in high-risk patients undergoing mechanical AVR with the ON-X prosthesis.</description><subject>Lessons from the Trials</subject><issn>2305-7823</issn><issn>2305-7823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkU1PGzEQhi3UqiDg1nPlI5XYsB7vh7eHVlFEC1KkIBQQN8trDxtXGzvY3lT013fDl6gPY4_96PXMvIR8ZvkEWFnAWafjZgI5ayawRw6A52VWC-Af3p33yXGMv_NxNTWvav6J7HOWQ9EUxQHZLldIr4KPG9TJbpFeK2f82v5FQxcuu6O3qh9vpy5Z7VU39CpZ7-ist85q1dNlsGM8ubpeTGfLr9_o3P_BQG2kLaaE4ZS2Q9qlNtHOe0PR-aFb_TgiH-9VH_H4ZT8kNz_Pl7OLbL74dTmbzjMNTKSswpoZURo91qqAsUaDEjXTDcvLYmxfALaNEaB4W-kS8koIVRjBuDBgQAh-SL4_626Gdo1Go0tB9XIT7FqFR-mVlf-_OLuSnd_KqqihatgocPIiEPzDgDHJtY0a-1459EOUAKyChoHYoafPqB7HGQPev33Dcvnklty5JXduSRjxL-9Le4NfveH_AJlgj9A</recordid><startdate>20190331</startdate><enddate>20190331</enddate><creator>Bouhout, Ismail</creator><creator>El-Hamamsy, Ismail</creator><general>Magdi Yacoub Heart Foundation</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190331</creationdate><title>The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?</title><author>Bouhout, Ismail ; El-Hamamsy, Ismail</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c218t-6e71d85dc944a2119c2a871c9105454282eb9d82a3b6c520688a4d8138d2d2883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Lessons from the Trials</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bouhout, Ismail</creatorcontrib><creatorcontrib>El-Hamamsy, Ismail</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Global Cardiology Science &amp; Practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bouhout, Ismail</au><au>El-Hamamsy, Ismail</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?</atitle><jtitle>Global Cardiology Science &amp; Practice</jtitle><addtitle>Glob Cardiol Sci Pract</addtitle><date>2019-03-31</date><risdate>2019</risdate><volume>2019</volume><issue>1</issue><spage>2</spage><epage>2</epage><pages>2-2</pages><issn>2305-7823</issn><eissn>2305-7823</eissn><abstract>Due to their durability, mechanical prostheses are frequently used for aortic valve replacement (AVR) in young adults. However, these valves are thrombogenic and require lifelong anticoagulation. Over the last few decades, efforts have been made towards the lowering of INR targets in an effort to reduce bleeding events without influencing the thromboembolic risk. The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT) was designed to compare standard versus low anticoagulation targets in high-risk patients undergoing mechanical AVR with the ON-X prosthesis.</abstract><cop>Qatar</cop><pub>Magdi Yacoub Heart Foundation</pub><pmid>31024944</pmid><doi>10.21542/gcsp.2019.2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2305-7823
ispartof Global Cardiology Science & Practice, 2019-03, Vol.2019 (1), p.2-2
issn 2305-7823
2305-7823
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6472691
source PubMed (Medline)
subjects Lessons from the Trials
title The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A12%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Prospective%20Randomized%20On-X%20Valve%20Anticoagulation%20Clinical%20Trial%20(PROACT):%20Lower%20is%20better,%20but%20is%20it%20good%20enough?&rft.jtitle=Global%20Cardiology%20Science%20&%20Practice&rft.au=Bouhout,%20Ismail&rft.date=2019-03-31&rft.volume=2019&rft.issue=1&rft.spage=2&rft.epage=2&rft.pages=2-2&rft.issn=2305-7823&rft.eissn=2305-7823&rft_id=info:doi/10.21542/gcsp.2019.2&rft_dat=%3Cproquest_pubme%3E2216291281%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c218t-6e71d85dc944a2119c2a871c9105454282eb9d82a3b6c520688a4d8138d2d2883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2216291281&rft_id=info:pmid/31024944&rfr_iscdi=true